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Striatal-enriched protein tyrosine phosphatase (STEP) has recently been implicated
in several neuropsychiatric disorders with signiﬁcant cognitive impairments, including
Alzheimer’s disease, schizophrenia, and fragile X syndrome. A model has emerged by
which STEP normally opposes the development of synaptic strengthening and that dis-
ruption in STEP activity leads to aberrant synaptic function. We review the mechanisms
by which STEP contributes to the etiology of these and other neuropsychiatric disorders.
These ﬁndings suggest that disruptions in STEP activity may be a common mechanism for
cognitive impairments in diverse illnesses.
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INTRODUCTION
Although the genetic basis of cognition is poorly understood, there
is a general agreement that normal cognitive function relies on
environmental, genetic, and molecular interactions (Heyes and
Huber, 2000). These interactions mediate the association between
speciﬁc behaviors, rewards, andpunishments, enabling individuals
to respond effectively to their environment. Cognitive impair-
ments present in numerous neuropsychiatric disorders, including
Alzheimer’s disease (AD; Folstein and Whitehouse, 1983), schiz-
ophrenia (SZ; Gold and Harvey, 1993), fragile X syndrome (FXS;
Smith, 1993), Huntington’s disease (HD; Bourne et al., 2006),
hypoxic–ischemic brain injury (Anderson and Arciniegas, 2010),
and alcohol use disorders (Bates et al., 2002).
Striatal-enriched protein tyrosine phosphatase (STEP) has
emerged as a critical enzyme in the signaling pathways that appear
to contribute to the cognitive impairments in each of these neu-
ropsychiatric disorders. STEP is a brain-speciﬁc phosphatase that
is highly expressed within the striatum (Lombroso et al., 1991) as
well as the cortex, hippocampus, and amygdala (Lombroso et al.,
1993; Boulanger et al., 1995).After transcription of the Ptpn5 gene,
alternative splicing produces mRNAs that encode four isoforms
(STEP20, STEP38, STEP46, and STEP61); however, only STEP46
and STEP61 contain an active phosphatase domain (Sharma et al.,
1995; Bult et al., 1996, 1997;Figure 1). STEP46 is expressed primar-
ily in the cytoplasm whereas STEP61 is targeted to the postsynaptic
density, extrasynaptic sites, and the endoplasmic reticulum (Lom-
broso et al., 1993; Boulanger et al., 1995; Goebel-Goody et al.,
2009).
STEP46 and STEP61 activity are regulated by the phosphoryla-
tion of a serine (Ser) residue (Ser49 and Ser221, respectively) within
a kinase-interacting motif (KIM), a binding site for all STEP sub-
strates. Phosphorylation at this site sterically prevents STEP from
associating with all of its substrates. Stimulation of glutamate
N -methyl-d-aspartate receptors (NMDARs) dephosphorylates
and activates STEP through a calcineurin/PP1 pathway (Paul et al.,
2003;Valjent et al., 2005).When activated, STEP dephosphorylates
tyrosine (Tyr) residues on its substrates, causing their inactivation,
or in the case of glutamate receptors, promoting their internal-
ization from synaptosomal surface membranes (Figure 2; only
NMDAR internalization shown for clarity).
Substrates of STEP include the GluN2B (previously called
NR2B) subunit of the NMDAR (Braithwaite et al., 2006), the
GluA2 (previously called GluR2) subunit of the α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR;
Zhang et al., 2008), as well as the kinases Fyn (Nguyen et al.,
2002) andPyk2 (Xuet al., 2010),and themitogen-activatedprotein
kinases (MAPKs) extracellular-regulated kinase 1/2 (ERK1/2) and
p38 (Munoz et al., 2003; Paul et al., 2003; Chen et al., 2009). Stimu-
lation of dopamineD1 receptors (D1Rs), or blockade of dopamine
D2 receptors (D2Rs), activates cyclic adenosine monophosphate
(cAMP)-dependent protein kinase A (PKA; Stoof and Kebabian,
1981), which phosphorylates and prevents STEP46 and STEP61
from interactingwith their substrates (Paul et al., 2000).D1R stim-
ulation can also activate a cAMP-independent cascade in which
Fyn phosphorylates GluN2B, potentiates NMDAR activity, and
activates ERK (Pascoli et al., 2011). These actions compliment
the actions of cAMP-dependent STEP inactivation, because inac-
tivation of STEP activates Fyn and ERK, and leads to NMDAR
internalization.
Synaptic plasticity refers to a change in synaptic efﬁcacy
between neurons, which is fundamental to learning, memory, and
cognition (Silva, 2003). This dynamic process requires synaptic
efﬁcacy to strengthen (long-term potentiation; LTP) or weaken
(long-term depression; LTD) in response to developmental and
environmental signals. Long-term potentiation is the most widely
supported molecular model of memory (Bliss and Collingridge,
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1993). It has recently become clear that LTP and LTD are not dis-
crete phenomena, but rather complimentary processes with com-
plex modulation that allow experiences to continuously reshape
neural function (Malenka and Bear, 2004). As is discussed fur-
ther below, STEP is currently believed to modulate both LTP and
LTD through its ability to regulate internalization of NMDARs
and AMPARs.
Glutamatergic transmission is essential for both LTP and LTD.
While LTP is facilitated by the coordinated actions of NMDARs
and AMPARs, metabotropic glutamate receptor (mGluR) activity
is important to the development of LTD. Moreover, glutamatergic
signaling is often modulated by dopaminergic (Centonze et al.,
2001; Calabresi et al., 2007), β-adrenergic (Vanhoose and Winder,
2003), and nicotinic cholinergic stimulation (Dajas-Bailador and
Wonnacott, 2004), as well as by other neuromodulators (Jin et al.,
2005; Mony et al., 2009).
Striatal-enriched protein tyrosine phosphatase has recently
been implicated in the pathophysiology of AD, schizophrenia,
FXS, HD, hypoxic–ischemic brain injury, and other neuropsy-
chiatric disorders. This important discovery suggests that several
FIGURE 1 | Structure of STEP. Both STEP46 and STEP61 contain a
kinase-interacting motif (KIM) domain, necessary for binding to all substrates,
and a protein tyrosine phosphatase (PTP) domain with a catalytic site (ˆ). In
addition, STEP61 has two polyproline (PP) domains, the ﬁrst of which interacts
with Fyn, and two transmembrane (TM) domains that target STEP61 to the
endoplasmic reticulum or postsynaptic density. Whereas STEP61 has two
serine (Ser) phosphorylation sites, STEP46 contains only one within the KIM
domain. The additional phosphorylation site on STEP61 may facilitate
proteolytic cleavage of STEP61 to produce an inactive STEP33 fragment that is
unable to bind substrates due to cleavage within the KIM domain.
FIGURE 2 | Regulation of STEP phosphorylation. D1R stimulation
phosphorylates and inactivates STEP through a cAMP/PKA pathway.
Glutamatergic stimulation of NMDARs reverses this process by
dephosphorylation and activation of STEP through a calcineurin/PP1 pathway.
Active STEP dephosphorylates regulatory tyrosines within STEP substrates.
STEP dephosphorylation of Fyn, Pyk2, ERK1/2, and p38 leads to their
inactivation; however, STEP dephosphorylation of GluN2B and GluA2 subunits
results in internalization of NMDARs and AMPARs, respectively, from
synaptosomal surface membranes. Only NMDARs are shown in the ﬁgure for
clarity.
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cognitive disorders that were previously regarded as distinct ill-
nesses may share a common molecular pathway. Other proteins
and STEP-independent mechanisms surely contribute to cogni-
tive impairments, but this review focuses on the role of STEP in
the pathogenesis of these neuropsychiatric disorders.
ALZHEIMER’S DISEASE: AMYLOID BETA LEADS TO
INCREASED STEP61 ACTIVITY
Alzheimer’s disease is a common form of dementia that causes
progressive cognitive impairment, most notably in memory and
semantic–lexical language (Huff et al., 1987). Cognitive impair-
ments are accompanied by behavioral alterations such as agitation,
dysphoria, and apathy (Mega et al., 1996). TheGermanpsychiatrist
Alois Alzheimer was the ﬁrst to describe the hallmark patho-
genic signs of the disease in brain autopsies: neuroﬁbrillary tangles
and plaques. This observation promoted the hypothesis that AD
progression is mediated by these neuroanatomical abnormalities
(Hardy and Higgins, 1992). In the 1980s, tau was identiﬁed as the
main constituent of neuroﬁbrillary tangles (Goedert et al., 1989)
and amyloid β (Aβ) proteins as the main constituent of plaques
(Tanzi et al., 1987). These ﬁndings led to the hypothesis that
hyperphosphorylated tau protein (Alonso et al., 1996) and insol-
uble aggregates of Aβ peptide formed from mutated amyloid
precursor protein (Cai et al., 1993; Suzuki et al., 1994) were a
possible mechanism underlying the pathology of AD.
The focus shifted in 1991 from extracellular deposits to a dis-
ruption in synaptic function when Terry et al. (1991) showed
that cortical synaptic density correlated more strongly with cogni-
tive impairments than plaque density. In support of the synaptic
hypothesis of AD, tau has been shown to reduce anterograde
transport evenbefore it aggregates in neuroﬁbrillary tangles (Man-
delkow et al., 2003).Moreover, solubleAβ oligomers impair synap-
tic function before neuronal loss occurs (Lue et al., 1999). These
oligomers directly bind to and chronically activate nicotinic acetyl-
choline receptors (nAChRs), causing sustained increases in intra-
cellular Ca2+ concentrations (Dougherty et al., 2003). In addition,
these oligomers reduceNMDAR-dependent synaptic transmission
and Ca2+ inﬂux, resulting in the loss of synapses in rat hippocam-
pal neurons (Cullen et al., 1996; Shankar et al., 2007). Finally,
exogenous application of Aβ to neuronal cell cultures and tissue
slices alters spine architecture and blocks LTP, and in vivo infu-
sions impair cognitive function in rodents (Walsh et al., 2002;
Lacor et al., 2007; Shankar et al., 2007, 2008).
The underlying mechanisms of Aβ-induced reductions in
synaptic function remain a focus of intense research. Snyder et al.
(2005) directly tested whether Aβ disrupts surface expression of
NMDARs. They demonstrated that Aβ binds α7 nAChRs, lead-
ing to Ca2+ inﬂux and activation of a calcineurin/PP1 pathway.
PP1 dephosphorylates and activates STEP, which inhibits Fyn
and promotes internalization of NMDARs and AMPARs from
synaptosomal membrane surfaces (Figure 3). Chin et al. (2005)
also found increased levels of STEP protein and decreased Fyn
activity in the dentate gyrus of a transgenic mouse model of AD
(the J20 mouse line).
Recently, Kurup et al. (2010) demonstrated that a second path-
way increases STEP61 activity in AD brains. This is due to a
disruption in the normal degradation of STEP61 as a result of
an Aβ-mediated inhibition of the proteasome. Because STEP61
is normally ubiquitinated and degraded by the ubiquitin protea-
some pathway, inhibition of the proteasome results in substantial
FIGURE 3 | Striatal-enriched protein tyrosine phosphatase and
Alzheimer’s disease. Cognitive impairments in AD appear before the
formation of Aβ plaques, suggesting that soluble Aβ may affect synaptic
function. Soluble Aβ increases both STEP levels and phosphorylation. First,
soluble Aβ inhibits STEP degradation by an Aβ-mediated inhibition of the
ubiquitin proteasome pathway. Second, soluble Aβ directly binds and activates
α7 nAChRs, leading to Ca2+ inﬂux and activation of calcineurin. Calcineurin/PP1
then dephosphorylates and activates STEP. Active STEP promotes the
dephosphorylation of Fyn, GluA2, and GluN2B (and other substrates not
depicted). Dephosphorylation of Fyn inactivates it whereas dephosphorylation
of GluN2B and GluA2 leads to NMDAR and AMPAR internalization from
synaptosomal surface membranes and disruption of synaptic function.
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increases in STEP61 in brain samples from both human AD and
mouse models.
If increased STEP61 levels contribute to the pathophysiology
of AD, then reducing them might reverse its biochemical and
cognitive deﬁcits. Zhang et al. (2010) tested this hypothesis in
a mouse model of the disease by genetically decreasing STEP
levels and demonstrating restored cognitive function in 6-month-
old AD mice null for STEP. Importantly, cognitive impairments
improved despite a continued elevation of Aβ and phosphory-
lated tau. It remains to be determined whether older AD mice
(i.e., 12-months old) with a similar genetic reduction in STEP also
have improved cognitive functioning. It should be emphasized that
STEP is one of over 400 proteins within neuronal spines, and that
STEP-independent pathways certainly contribute to the pathogen-
esis of AD as well as the other disorders discussed in subsequent
sections.
SCHIZOPHRENIA: STEP CONTRIBUTES TO THE BENEFICIAL
EFFECTS OF NEUROLEPTICS
Schizophrenia is characterized by cognitive and emotional
deterioration, with symptoms typically emerging during
young adulthood. Positive symptoms include delusions,
disordered thought and speech, and hallucinations. Negative
symptoms, which are deﬁcits in emotional and mental processes,
include blunted affect, poverty of speech, anhedonia, and aso-
ciality. In addition to positive and negative symptoms, cognitive
impairments including deﬁcits in executive functioning predate
the onset of the above symptoms and persist when these subside.
Schizophrenia was considered untreatable until the introduc-
tion of the ﬁrst neuroleptic, chlorpromazine, in 1952. The mech-
anism of action of these “typical” antipsychotics is unknown,
despite their efﬁcacy in the treatment of SZ. The dopamine
hypothesis of SZ emerged from the discovery that typical antipsy-
chotics, such as chlorpromazine, block D2Rs, and their clinical
potency is related to the afﬁnity of antipsychotic medications for
this receptor (Seeman et al., 1975; Creese et al., 1976).
Although dopamine levels are increased in the striatum (Breier
et al., 1997) and decreased in the frontal cortex (Dolan et al., 1995),
recent evidence suggests that the pathophysiology of SZ includes
deﬁcits in other neurotransmitter systems, in particular gluta-
matergic hypofunction (Jentsch and Roth, 1999). This is due in
part to the fact that the dopamine hypothesis of SZdoes not appear
to explain the SZ-like symptoms induced by non-competitive
NMDAR antagonists, such as phencyclidine and ketamine. Fur-
ther support for the glutamate hypothesis comes from research in
animal models and human subjects. Mice expressing 5% of the
normal levels of GluN1 display SZ-like behaviors, which are atten-
uated by treatment with the antipsychotics haloperidol and cloza-
pine (Mohn et al., 1999). In human patients, Pilowsky et al. (2006)
used in vivo positron emission tomography to demonstrate reduc-
tions in hippocampal NMDAR binding in medication-free but
not antipsychotic-treated schizophrenics. Moreover, postmortem
investigation of schizophrenic brains reveals that GluN1 mRNA
levels are reduced by 30% in the superior temporal cortex of cog-
nitively impaired schizophrenics, a deﬁcit that is correlated with
antemortem severity of cognitive impairment (Humphries et al.,
1996). Finally, the administration of glycine and d-serine, poten-
tiators of NMDAR function, improves symptoms in medicated
schizophrenics (Heresco-Levy et al., 1999; Kantrowitz et al., 2010).
Recent studies suggest that STEP plays a role in mediating the
beneﬁcial effects of neuroleptics. Both typical and atypical antipsy-
chotics regulate cAMP-dependent PKAactivity in the striatumand
medial prefrontal cortex (Turalba et al., 2004). Recently,Carty et al.
(2010) showed that both acute and subchronic administration of
haloperidol, clozapine, and risperidone result in a PKA-mediated
phosphorylation of STEP (Figure 4). As discussed above, this
prevents STEP from interacting with its substrates. In addition,
neuroleptic-mediated activation of PKA results in the phospho-
rylation and activation of DARPP-32. DARPP-32 is an indirect
inhibitor of STEP through its inhibition of PP1,which dephospho-
rylates and inactivates STEP. Consequently, both PKA activation
and PP1 inactivation contribute to decreased STEP activity.
DARPP-32 also activates STEP substrates through STEP-
independent pathways. For example, ERK is activated by DARPP-
32 through the inhibition of PP1, leading to activation of upstream
modulators of ERK activity, such as mitogen-activated protein
kinase kinase (MEK;Valjent et al., 2005). These results suggest that
neuroleptics exert their beneﬁcial effects at least in part through
D2R/PKA-mediated phosphorylation and inactivation of STEP,
promoting Tyr phosphorylation of STEP substrates that include
GluN2B-containing NMDARs,which now trafﬁc to synaptosomal
surface membranes.
FIGURE 4 | Striatal-enriched protein tyrosine phosphatase and
schizophrenia. Deﬁcits in glutamatergic neurotransmission are believed to
underlie the pathophysiology of SZ. Administration of typical and atypical
antipsychotics, which are D2R antagonists (ant), increase PKA-mediated
phosphorylation of STEP. Inactivation of STEP results in increased trafﬁcking
of NMDARs to synaptosomal surface membranes. This suggests that the
beneﬁcial effects of neuroleptics are mediated, at least in part, through
restoration of NMDAR levels at synaptic sites.
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FRAGILE X SYNDROME: THE FMRP PROTEIN NEGATIVELY
REPRESSES STEP
Fragile X syndrome is an X-linked, monogenic neurological dis-
order and the leading cause of inherited mental retardation. It
is characterized by hyperactivity, auditory hypersensitivity and
audiogenic seizures, developmental delays, emotional dysfunc-
tion, and cognitive impairment (Visootsak et al., 2005; Koukoui
and Chaudhuri, 2007). Common cognitive impairments in FXS
include impaired quantitative skills, short-term memory, spatial
visualization, and visual–motor coordination (Freund and Reiss,
1991).
Fragile X syndrome results from an expanded 5′-CCG repeat
region in the ﬁrst exon of the fragile X mental retardation 1 (Fmr1)
gene (Xq27.3). The increased number of cytosines are methy-
lated and interfere with the transcription of Fmr1 mRNA once the
expansion exceeds 200 repeats (Oberle et al., 1991). The protein
encoded by Fmr1, fragile X mental retardation protein (FMRP),
is a cytosolic RNA-binding protein that associates with polyribo-
somes and the RNA-silencing complex, functioning as a negative
repressor of translation (Laggerbauer et al., 2001; Li et al., 2001;
Garber et al., 2006). Because FMRP and polyribosomes are present
in dendritic spines, it was suggested that FMRPmodulates synaptic
activity through its ability to repress local translation of mRNAs
(Weiler and Greenough, 1999). Synaptic activity was proposed
to remove FMRP inhibitory effects, resulting in local translation
of mRNAs (Bear et al., 2004). In this way, RNA-binding proteins,
such as FMRP, inﬂuence synaptic plasticity by controlling activity-
dependent regulation of mRNA localization and translation (Ule
and Darnell, 2006).
In support of this hypothesis, FMRP is quickly synthesized and
localized to dendrites after stimulation of group I mGluRs (Todd
et al., 2003; Antar et al., 2004). Activation of mGluRs stimulates
protein synthesis-dependent LTD in dendrites (Huber et al., 2000,
2001) and results in a rapid loss of synapticNMDARs andAMPARs
(Snyder et al., 2001). Fmr1 KO mice display increased protein
synthesis (Qin et al., 2005), enhanced hippocampal LTD (Huber
et al., 2002), as well as abnormal synaptic morphology, includ-
ing immature development of dendritic spines (Irwin et al., 2000),
delayed spine turnover and stabilization (Cruz-Martin et al., 2010),
increased spine density (Comery et al., 1997), and a decreased
number of functional synapses (Pfeiffer and Huber, 2007).
It is believed that FMRP regulates mGluR-dependent LTD by
tightly controlling protein synthesis and that decreased FMRP
expression elevates synaptic protein levels, which exaggerate
mGluR-dependent LTD and disrupt synaptic morphology (Bear
et al., 2004; Ronesi and Huber, 2008). In Fmr1 KO mice, mGluR-
dependent LTD no longer requires new protein synthesis, sug-
gesting that elevated levels of synaptic proteins, which would
normally be inhibited by FMRP, enable LTD to persist without de
novo protein synthesis (Nosyreva and Huber, 2006). For example,
Fmr1 KO mice exhibit decreased surface expression of NMDARs
(Eadie et al., 2010) and GluA1-containingAMPARs (Li et al., 2002;
Suvrathan et al., 2010), which is most likely a consequence of
uninhibited mGluR signaling (Nakamoto et al., 2007). Although
it is known that Fmr1 KO exaggerates mGluR-dependent LTD by
decreasing synaptic glutamate receptor expression, it is not known
how this occurs.
Zhang et al. (2008) demonstrated that STEP translation is
increased in the mouse hippocampus upon mGluR5 stimulation,
resulting in AMPAR internalization through Tyr dephosphoryla-
tion of the GluA2 subunit, although the exact Tyr residue is not yet
known (Figure 5). More recently, it was shown that STEP mRNA
associates with FMRP and that STEP protein levels are elevated in
Fmr1 KO mice (Goebel-Goody et al., 2010). In addition, progeny
were generated by crossing Fmr1 and STEP KO mice to produce
mice with lowered STEP levels despite the continued presence of
the Fmr1 mutation. These mice display fewer audiogenic seizures
and less spatial anxiety than Fmr1 KO mice. These results sug-
gest that some of the deﬁcits in animal models of FXS result from
the failure of FMRP to suppress STEP translation upon mGluR
stimulation, allowing increased STEP levels to inappropriately
internalize NMDARs and AMPARs.
THE ROLE OF STEP IN OTHER NEUROPSYCHIATRIC
DISORDERS
HUNTINGTON’S DISEASE
Huntington’s disease is an autosomal dominant neurodegener-
ative disease caused by abnormal expansion of a CAG codon
in exon 1 of the huntingtin (HTT ) gene (4p16.3). The expan-
sion results in a mutant HTT (mHTT) protein that contains
excessive polyglutamine residues (The Huntington’s Disease Col-
laborative Research Group, 1993). Projection neurons, which are
the majority of striatal neurons, are speciﬁcally affected in HD
(Reiner et al., 1988). HD symptoms such as chorea, a movement
disorder, and cognitive impairments have been attributed to pro-
gressive excitotoxicity of these projection neurons resulting from
NMDAR activation, which destroys striatal innervation of other
brain regions (DiFiglia, 1990; Fan and Raymond, 2007). Cogni-
tive impairments common to HD patients are loss of initiative,
poor perseverance, impaired judgment, and emotional blunting
FIGURE 5 | Striatal-enriched protein tyrosine phosphatase and fragile
X syndrome. FMRP is an RNA-binding protein that represses mRNA
translation in dendrites. FMRP is absent in FXS, and as a result there is a
disruption in mRNA translation. STEP mRNA associates with FMRP, and
STEP protein levels are increased in Fmr1 KO mice. The higher levels of
active STEP protein are thought to disrupt synaptic function by
dephosphorylation of STEP substrates.
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(Craufurd et al., 2001). In addition, attention, executive function,
language comprehension, and visuospatial immediatememory are
impaired as the disease progresses (Bachoud-Levi et al., 2001).
Although mHTT is present at birth in affected individuals,
symptoms typically begin in middle age. Transgenic lines of mice
expressing mHTT are resistant to striatal toxicity induced by
quinolinic acid, an NMDAR agonist, suggesting that compen-
satory mechanisms in the brain protect against the toxic effect
of mHTT (Hansson et al., 1999). Similar mechanisms in humans
might explain why HD is a late-onset disorder.
Several lines of evidence suggest that in animal models of HD,
mHTT disrupts PKA and calcineurin activity, both important reg-
ulators of STEP activity. Dopamine D1-like receptor binding in
R6/2 mice is signiﬁcantly reduced at 8 weeks whereas D1R mRNA
is reduced by 4weeks, well before the onset of symptoms (Cha
et al., 1998). Moreover, cAMP synthesis declines in HdhQ111 mice
at an early age (10weeks) and results in decreased PKA activ-
ity and cAMP-responsive element-mediated gene transcription
(Gines et al., 2003). In support of decreased D1R and PKA activ-
ity, proteins in the D1R/PKA pathway, such as DARPP-32, are
also downregulated in medium spiny neurons of the striatum of
transgenic HD mice (Bibb et al., 2000). In addition, calcineurin
activity is decreased in R6/1 and Tet/HD94 mice (Xifro et al.,
2009), which may be the result of an abnormal protein interac-
tion between mHTT and calmodulin (Bao et al., 1996), which is
required to activate calcineurin.
Saavedra et al. (2011) recently demonstrated reduced STEP lev-
els in the striatum and cortex and increased phosphorylated STEP
in the striatum, cortex, and hippocampus of several animalmodels
of HD, including R6/1, R6/2, and Tet/HD94. Both of these events
would decrease the ability of STEP to dephosphorylate its sub-
strates. Intrastriatal injections of quinolic acid resulted in elevated
phosphorylated STEP levels in R6/1 mice and sustained ERK2 sig-
naling, suggesting that mHTT downregulates STEP, thereby inac-
tivating it and promoting a compensatory activation of ERK2 and
resistance to mHTT-induced excitotoxicity. Furthermore, intras-
triatal injection of TAT–STEP, a substrate-trapping form of STEP,
increases quinolinic acid-induced cell death in R6/1 mice whereas
mHTT transgene shutdown reestablishes STEP expression in
Tet/HD94 mice. Moreover, mHTT activates ERK1/2, promotes
cell survival, and protects against mHTT-induced excitotoxicity
in PC12 and striatal cultures (Apostol et al., 2006).
Resistance to NMDA toxicity, however, is correlated with the
appearance of nuclear inclusions and behavioral deﬁcits in mice
transgenic for exon 1 of HTT (Hansson et al., 2001). In the
YAC128 mouse model of HD, cognitive dysfunction precedes
both neuropathological alterations and motor dysfunction (Van
Raamsdonk et al., 2005).Moreover, impaired spatial cognition and
synaptic plasticity in CA1 and the dentate gyrus occurs before the
manifestation of an overt phenotype in R6/2 mice (Murphy et al.,
2000). Therefore,while resistance to excitotoxicity delays neuronal
loss in the early stages of HD, it also contributes to the development
of synaptic dysfunction that likely contributes to the observed cog-
nitive impairment in HD. In summary, STEP is downregulated
in HD and promotes resistance to mHTT-induced excitotoxicity,
most likely due in part to STEP inactivation and more sustained
ERK2 activation.
ALCOHOL-INDUCED COGNITIVE IMPAIRMENT
Alcohol-induced cognitive impairment is well-documented in
alcohol use disorders, and it is believed that inhibition of NMDAR
function, especially in the hippocampus, partly contributes to
the ability of alcohol to disrupt memory and learning (White
et al., 2000). Numerous kinases (PKA, protein kinase C, calcium-
/calmodulin-dependent protein kinase II, cyclin-dependent pro-
tein kinase 5) and phosphatases (calcineurin) regulate the phos-
phorylation state of Ser and Tyr residues on NMDARs and con-
tribute to the behavioral effects of alcohol (Ron, 2004). Previously,
it was demonstrated that ethanol reduces Tyr phosphorylation of
GluN2A/GluN2B subunits of NMDARs (Alvestad et al., 2003) and
treatment with tyrosine phosphatase inhibitors reduces the abil-
ity of ethanol to inhibit Tyr phosphorylation of GluN2, suggesting
that tyrosine phosphatases have an important role inmediating the
effects of alcohol on NMDAR function (Ferrani-Kile et al., 2003).
Recently, it was suggested that STEP mediates aspects of the
effects of alcohol on neurons. Hicklin et al. (2011) demon-
strated that ethanol’s inhibition of NMDAR function (as
measured by electrophysiology) was lost in STEP KO mice.
The functional consequence of ethanol in inhibiting
fear-conditioned responses was also attenuated in STEP KO
mice. Moreover, restoring STEP in neuronal cultures and slices
derived from STEP KO mice restored ethanol-induced biochem-
ical and electrophysiological deﬁcits. These results suggest that
STEP may be required for the amnesiac effects of ethanol by
dephosphorylating GluN2B subunits.
These experiments were conducted using hippocampal neu-
rons, but acute ethanol administration in the dorsomedial
striatum similarly impairs NMDAR-dependent LTP and dose-
dependently promotes LTD (Yin et al., 2007). Wang et al.
(2007, 2010) demonstrated that chronic administration of ethanol
increases GluN2B phosphorylation and Fyn activation in the
dorsomedial striatum. These results are unsurprising, how-
ever, considering the differential effects of acute and chronic
ethanol treatments on NMDAR function. For example, in cor-
tical neurons, chronic ethanol treatment has the opposite effect
as acute ethanol treatment, enhancing NMDAR binding (Hu and
Ticku, 1995) and potentiating NMDAR-mediated excitotoxicity
(Chandler et al., 1993). Future studies should determine whether
STEPmediates the effects of ethanol in the striatumas it does in the
hippocampus. In addition, chronic ethanol treatments should be
utilized todetermine the potential role of STEP in the development
of NMDAR upregulation and sensitization.
HYPOXIC–ISCHEMIC BRAIN INJURY
Hypoxia is the reduction of blood oxygenation to the brain
whereas ischemia is the reduction of blood perfusion to the brain.
Hypoxic–ischemic brain injury caused by perinatal complications
during childbirth or stroke is a leading cause of mental retardation
and cognitive impairment. In addition, hypoxic–ischemic brain
injury caused by stroke increases the risk for dementia; it is esti-
mated that up to a third of stroke patients develop dementiawithin
3months (Pohjasvaara et al., 1998). Hypoxia–ischemia results in
neuronal loss from glutamate excitotoxicity and increased intra-
cellular Ca2+ levels (Benveniste, 1991). Excessive stimulation of
NMDARs leads to a massive and rapid inﬂux of Ca2+, which
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generates nitric oxide and free radicals (Iadecola, 1997). In addi-
tion, intracellular changes in NMDAR subunit phosphorylation
as well as MAPK activation following ischemia further exacerbate
glutamate excitotoxicity and neuronal loss (Nozaki et al., 2001;
Matsumoto et al., 2002). Hippocampal regions, such as CA1, are
especially vulnerable to glutamate excitotoxicity (Kirino and Sano,
1984; Nitatori et al., 1995). Damage to the hippocampus is com-
monly observed in both vascular and senile dementia, and it is
associated with cognitive impairment (Ball et al., 1985; Kril et al.,
2002).
Gurd et al. (1999) were the ﬁrst to report that cerebral hypoxia–
ischemia results in the calpain-mediated proteolysis of STEP61 to
STEP33, which is released into the cytoplasm. Soon after, Nguyen
et al. (1999) demonstrated that STEP61 cleavage requiresNMDAR-
mediated Ca2+ inﬂux. The cleavage site is in the middle of the
substrate-binding KIM domain (Xu et al., 2009), and it was later
determined that although STEP33 is catalytically active, it is unable
to bind or dephosphorylate its substrates (Braithwaite et al., 2008;
Xu et al., 2009). Extrasynaptic NMDAR stimulation results in
the cleavage of STEP61 by calpain and the activation of p38 and
cell death (Xu et al., 2009). Thus, cleavage of STEP61 to STEP33
contributes to glutamate excitotoxicity by inhibiting NMDAR
internalization from synaptosomal surface membranes and pro-
moting cell death pathways.
FUTURE DIRECTIONS
Homeostasis, a cornerstone of biological organisms, regulates
physiological states to promote stability despite ﬂuctuating condi-
tions. Neural activity is subject to homeostatic control, optimizing
activity-dependent synaptic plasticity to avoid over- or under-
excitation (Turrigiano and Nelson, 2004). STEP may contribute to
this homeostatic control of synaptic plasticity by providing a tonic
brake on the induction of LTP (Pelkey et al., 2002). In other words,
NMDAR-mediated STEP activation modulates LTP by removing
glutamate receptors from synaptic membranes. Conversely, STEP
may be inactivated during periods of synaptic quiescence, result-
ing in increased surface expression of glutamate receptors. Finally,
note that in the absenceof STEP,glutamate receptorswould rapidly
accumulate on synaptic membranes and neurons would no longer
be responsive to synaptic or modulatory inputs.
Striatal-enriched protein tyrosine phosphatase is uniquely
positioned to modulate LTP by internalizing NMDARs and
AMPARs from the plasma membrane and curtailing the enhance-
ment of LTP by the MAPK pathway. Because the removal of
NMDARs and AMPARs is believed to be one mechanism involved
in LTD, STEP can balance the degree to which synapses strengthen
and weaken during learning and memory, maintaining neural
homeostasis (Xiao et al., 1994). The involvement of STEP in
homeoplastic synaptic regulation requires further investigation.
Elevated STEP levels and excessive internalization of NMDARs
or AMPARs in AD, SZ, and FXS would result in a homeostatic
imbalance, shifting synaptic plasticity toward LTD and synaptic
weakening. As a result, systems critical for learning, memory, and
cognition, such as those involving the hippocampus, would settle
into a quiescent state, resulting in cognitive impairment. Con-
versely, the absence of STEP might facilitate learning. Indeed,
Venkitaramani et al. (2011) demonstrated that STEP KO mice
display enhanced hippocampal-dependent learning and cognitive
performance. This effect parallels increased phosphorylation of
STEP substrates (ERK1/2, GluN2B, Pyk2) and increased synap-
tosomal expression of GluN1/GluN2B-containing NMDARs and
GluA1/GluA2-containing AMPARs.
Striatal-enriched protein tyrosine phosphatase levels are
decreased in HD, yet HD also results in cognitive impairment.
Before the onset of neuropathological abnormalities, mHTT
impairs axonal transport and vesicular trafﬁcking (Trushina et al.,
2004) and represses nuclear transcription (Kegel et al., 2002).
Inadequate neurotransmitter release or protein synthesis in the
synapse could result in dysfunctional synaptic plasticity. For exam-
ple, mHTT results in decreased glutamate neurotransmission
(Usdin et al., 1999) and decreased transcription of brain-derived
neurotrophic factor (Zuccato et al., 2001), a crucial modulator
of synaptic plasticity (Bramham and Messaoudi, 2005). Although
STEP is initially neuroprotective in preventing immediate,mHTT-
induced excitotoxicity, it is unable to prevent the mHTT-induced
synaptic dysfunction and eventual neurite dystrophy caused by
aberrant axonal transport and nuclear transcription.
On the other hand, cognitive impairments observed after
hypoxic–ischemic brain injury are caused by excitotoxicity and
synaptic destruction rather than altered synaptic function. In
rodents, neurotoxic lesions of the hippocampus with NMDA
result in cognitive deﬁcits, especially in spatial learning and
memory (Hicks et al., 1993; Deacon et al., 2002). As previously
mentioned, hypoxia–ischemia results in excitotoxicity through
NMDAR-mediated cleavage of STEP61 into STEP33, which is no
longer able to dephosphorylate and internalize NMDARs on the
plasma membrane. Rather than decreasing STEP levels or activ-
ity,hypoxic–ischemic brain injury could be attenuated by elevating
STEP levels (Braithwaite et al., 2008) or blocking the calpain cleav-
age site (Xu et al., 2009), thereby enhancing the ability of STEP to
dephosphorylate p38 and protect neurons against excitotoxicity.
In conclusion, STEP contributes to cognitive deﬁcits in sev-
eral disorders by regulating the activity of key signaling proteins
and the trafﬁcking NMDARs and AMPARs to synaptic mem-
branes. Although the mechanisms of impaired synaptic plasticity
vary, alterations in NMDAR and AMPAR trafﬁcking contribute to
the disruption of synaptic function in each disorder. In AD, SZ,
and FXS, elevated STEP activity causes excessive glutamate recep-
tor internalization from synaptosomal surface membranes and
decreased synaptic plasticity. In HD, STEP downregulation is ini-
tially neuroprotective to mHTT-induced glutamate excitotoxicity,
but at the cost of disrupting synaptic plasticity and causing cogni-
tive impairment. In hypoxic–ischemic brain injury, STEP cleavage
and the loss of substrate-binding facilitates NMDAR-mediated
glutamate excitotoxicity, resulting in neuronal loss, especially in
the hippocampus. Although speciﬁc inhibitors are being devel-
oped, such as glutamate antagonists for schizophrenia and calpain
inhibitors for ischemia–hypoxia, STEP may prove to be a novel
therapeutic target for multiple disorders that impair cognitive
function.
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